Leonhard Müllauer

Pathologist/Molecular Pathologist/Associate Professor

Medical University of Vienna

Austria

Research Interests

Explore related searches

Professors in Austria Professors in Immunology Immunology professors in Austria

Contact this professor

ORCID

Google Scholar

Academic Page

About

Leonhard Müllauer is an Associate Professor at the Medical University of Vienna, Austria. His research primarily focuses on molecular pathology, including the therapeutic effects of drugs in high-grade serous ovarian cancer, gene fusions in juvenile xanthogranuloma, and liquid biopsy disease monitoring for medulloblastoma. He has published extensively on topics such as tumorigenesis in Lynch syndrome and the clinical response to targeted therapies in various malignancies.

Leonhard Müllauer

Research Interests

Explore related searches

Contact this professor

About

Articles (16)

ctDNA as an Objective Marker for Postoperative Residual Disease in Primary Advanced High-Grade Serous Ovarian Cancer

Therapeutic Effects of Lurbinectedin in PARP Inhibitor-Resistant High-Grade Serous Ovarian Cancer Using Patient-Derived Cell Lines and Organoid Models

NTRK1 Gene Fusions Are Frequent in Juvenile Xanthogranuloma

Nfe2l2/NRF2 Deletion Attenuates Tumorigenesis and Increases Bacterial Diversity in a Mouse Model of Lynch Syndrome

Proof-of-Concept for Liquid Biopsy Disease Monitoring of MYC-Amplified Group 3 Medulloblastoma by Droplet Digital PCR

Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer

CLINICAL RESPONSE TO THE PDGFRA/KIT INHIBITOR AVAPRITINIB IN PEDIATRIC AND YOUNG ADULT HIGH-GRADE GLIOMA PATIENTS WITH H3K27M OR PDGFRA GENOMIC ALTERATIONS

Short‐term and sustained clinical response following thymectomy in patients with myasthenia gravis

Tumour immune microenvironment in resected thymic carcinomas as a predictor of clinical outcome

Corrected Allele Frequency of BRCA1/2 Mutations Is an Independent Prognostic Factor for Treatment Response to PARP-Inhibitors in Ovarian Cancer Patients

Trabectedin Is Active against Two Novel, Patient-Derived Solitary Fibrous Pleural Tumor Cell Lines and Synergizes with Ponatinib

Short-term and sustained clinical response following thymectomy in patients with myasthenia gravis

Application of mTORC1 Inhibitors for Tissue-Agnostic Management of Standard-Therapy-Refractory Solid Tumors

Application of mTORC1 Inhibitors for Tissue-Agnostic Management of Standard-Therapy-Refractory Solid Tumors

Unique Finding of a Primary Central Nervous System Neuroendocrine Carcinoma in a 5-Year-Old Child: A Case Report.

Trabectedin Is Active against Two Novel, Patient-Derived Solitary Fibrous Pleural Tumor Cell Lines and Synergizes with Ponatinib

Collaborators (22)

Hossein Taghizadeh

Christoph Gasche

Thomas Czech

Ana-Iris Schiefer

Bernhard Moser

Kristine Jimenez

Daniela Loetsch

Amedeo Azizi

Bahil Ghanim

Cecilia Veraar

Christoph Grimm

Martin Krenn

Georg Widhalm

Stephan Polterauer

Andreas Peyrl

Walter Berger

Hakan Cetin

Christian Dorfer

Luzia Berchtold

Johannes Gojo

Michaela Lang

Jakob Rath

How do I reach out?

Meet Kite AI